Possible relationship between the use of próton pump inhibitors and neoplasms

• Autor(a) principal: Paiva, Alyne de Araújo
• Data de Publicação: 2021
• Outros Autores: Lima, Daniel Barbosa, Freitas, David Danisio Silva de, Costa Neto, Francisco de Nojosa, Oliveira Filho, Francisco Hildebrando Moreira de, Farias, Lucas Benjamim Pereira, Silva Neta, Maria das Graças Resende da, Guerra, Ariellen Martins, Silva, Guilherme Araújo da, Machado , Antônio Victor de Oliveira, Marques , Célia Barros de Sousa, Nogueira , Raquel Araújo, Gomes , Ana Clara Correia, Pereira Júnior, José Lopes
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/23310
• topic: Proton bomb inhibitors; Stomach; Histopathological changes.; Inhibidores de la bomba de protones; Estómago; Cambios histopatológicos.; Inibidores de bomba de prótons; Estômago; Alterações histopatológicas.

Introduction: The prolonged use of proton pump inhibitors has become common and has been widely applied in the treatment of these various gastrointestinal diseases and studies have shown a possible relationship between the use of these drugs and histopathological changes in the gastric region. Objective: To understand the possible relationship between the use of proton pump inhibitors (PPIs) and gastric disorders. Methodology: For this, the descriptors in the Bireme, Pubmed, Scielo databases were applied, considering the studies of the last 16 years. Expected results: The studies are expected to answer our questions and serve as a basis for further studies to be carried out. Conclusion: About the possible relationship between the use of proton pump inhibitors and cancer, it is important to emphasize that, with continuous use and in long-term therapy, this class of drug triggered hypergastrinemia in a large majority of patients and a high incidence of ECL cell hyperplasia. Regarding its association with H. pylori, positive patients who had been treated with PPIs for a long period had an increased risk of body atrophy compared to patients who were negative for Hp. Finally, there was no evidence of the association of PPIs with the induction or elevation of those rich in cancer.